You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

INGREZZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ingrezza, and when can generic versions of Ingrezza launch?

Ingrezza is a drug marketed by Neurocrine and is included in two NDAs. There are twenty-two patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and twenty-five patent family members in thirty-five countries.

The generic ingredient in INGREZZA is valbenazine tosylate. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ingrezza

A generic version of INGREZZA was approved as valbenazine tosylate by LUPIN LTD on April 5th, 2024.

  Try for Free

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for INGREZZA?
  • What are the global sales for INGREZZA?
  • What is Average Wholesale Price for INGREZZA?
Drug patent expirations by year for INGREZZA
Drug Prices for INGREZZA

See drug prices for INGREZZA

Recent Clinical Trials for INGREZZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Neurocrine BiosciencesPhase 4
Stephen RuedrichPhase 4
Michael BlochPhase 2

See all INGREZZA clinical trials

Pharmacology for INGREZZA
Paragraph IV (Patent) Challenges for INGREZZA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
INGREZZA Capsules valbenazine tosylate 60 mg 209241 1 2022-02-14
INGREZZA Capsules valbenazine tosylate 40 mg and 80 mg 209241 4 2021-04-12

US Patents and Regulatory Information for INGREZZA

INGREZZA is protected by thirty-three US patents and two FDA Regulatory Exclusivities.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 AB RX Yes No ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Neurocrine INGREZZA SPRINKLE valbenazine tosylate CAPSULE;ORAL 218390-002 Apr 30, 2024 RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for INGREZZA

When does loss-of-exclusivity occur for INGREZZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2819
Patent: FORMULACIÓN Y COMPOSICIONES DE VALBENAZINA DE ALTA DOSIS, MÉTODOS Y EQUIPOS RELACIONADOS
Estimated Expiration: ⤷  Try for Free

Australia

Patent: 18335259
Patent: High dosage valbenazine formulation and compositions, methods, and kits related thereto
Estimated Expiration: ⤷  Try for Free

Brazil

Patent: 2020005373
Patent: formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 76000
Patent: FORMULATION DE VALBENAZINE A DOSAGE ELEVE ET COMPOSITIONS, PROCEDES ET KITS ASSOCIES (HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS, AND KITS RELATED THERETO)
Estimated Expiration: ⤷  Try for Free

China

Patent: 1372567
Patent: 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 (High dosage valbenazine formulation and compositions, methods, and kits related thereto)
Estimated Expiration: ⤷  Try for Free

Eurasian Patent Organization

Patent: 2090809
Patent: ВЫСОКОДОЗОВЫЙ СОСТАВ ВАЛБЕНАЗИНА И КОМПОЗИЦИИ, СПОСОБЫ И НАБОРЫ, СВЯЗАННЫЕ С НИМ
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 84333
Patent: FORMULATION DE VALBENAZINE À DOSAGE ÉLEVÉ ET COMPOSITIONS, PROCÉDÉS ET KITS ASSOCIÉS (HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS, AND KITS RELATED THERETO)
Estimated Expiration: ⤷  Try for Free

Israel

Patent: 3300
Patent: פורמולציית ולבנאזין במינון גבוה ותכשירים, שיטות וערכות קשורות להן (High dosage valbenazine formulation and compositions, methods, and kits related thereto)
Estimated Expiration: ⤷  Try for Free

Patent: 1770
Patent: פורמולציית ולבנאזין במינון גבוה ותכשירים, שיטות וערכות קשורות להן (High dosage valbenazine formulation and compositions, methods, and kits related thereto)
Estimated Expiration: ⤷  Try for Free

Patent: 9802
Patent: פורמולציית ולבנאזין במינון גבוה ותכשירים, שיטות וערכות קשורות להן (High dosage valbenazine formulation and compositions, methods, and kits related thereto)
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 50006
Estimated Expiration: ⤷  Try for Free

Patent: 20534305
Patent: 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 20002841
Patent: FORMULACION DE VALBENAZINA DE ALTA DOSIS Y COMPOSICIONES, METODOS Y KITS RELACIONADOS CON LA MISMA. (HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS, AND KITS RELATED THERETO.)
Estimated Expiration: ⤷  Try for Free

Morocco

Patent: 175
Patent: FORMULATION DE VALBENAZINE À DOSAGE ÉLEVÉ ET COMPOSITIONS, PROCÉDÉS ET KITS ASSOCIÉS
Estimated Expiration: ⤷  Try for Free

Taiwan

Patent: 1919622
Patent: High dosage VALBENAZINE formulation and compositions, methods, and kits related thereto
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INGREZZA around the world.

Country Patent Number Title Estimated Expiration
Malaysia 193767 VALBENAZINE SALTS AND POLYMORPHS THEREOF ⤷  Try for Free
Lithuania 3875459 ⤷  Try for Free
Mexico 2022000559 METODOS PARA LA ADMINISTRACION DE CIERTOS INHIBIDORES DE VMAT2 A PACIENTES CON INSUFICIENCIA RENAL GRAVE. (METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS TO PATIENTS WITH SEVERE RENAL IMPAIRMENT.) ⤷  Try for Free
Spain 2857085 ⤷  Try for Free
Canada 2668689 COMPOSES 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL SUBSTITUES ET PROCEDES ASSOCIES (SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO) ⤷  Try for Free
Croatia P20240304 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for INGREZZA (Valbenazine)

Introduction

INGREZZA (valbenazine) is a medication developed by Neurocrine Biosciences, Inc., primarily used to treat tardive dyskinesia and chorea associated with Huntington's disease. The drug has shown significant growth and financial success, making it a key player in the neuroscience pharmaceutical market.

Market Demand and Growth

INGREZZA has experienced robust growth driven by strong underlying patient demand. In the second quarter of 2024, INGREZZA net product sales reached $580 million, representing a 32% year-over-year growth compared to the same period in 2023[1].

Similarly, in the third quarter of 2024, INGREZZA net product sales were $613 million, marking a 26% year-over-year growth. This growth is attributed to the increasing adoption of the drug for treating tardive dyskinesia and Huntington's disease chorea, as well as improvements in gross-to-net dynamics[5].

Financial Performance

The financial performance of INGREZZA has been impressive, reflecting the drug's market success.

Quarterly and Annual Sales

  • In the fourth quarter of 2023, INGREZZA net product sales were $500 million, with full-year sales reaching $1.84 billion, representing a 29% year-over-year growth[2].
  • For 2024, the net product sales guidance for INGREZZA has been raised to $2.30 - $2.32 billion, indicating continued strong growth[5].

Revenue and Earnings

  • The revenue growth for Neurocrine Biosciences, driven largely by INGREZZA, stands at 25.72% over the last twelve months as of Q3 2024, with quarterly revenue growth at 24.72%[3].
  • Non-GAAP net income and earnings per share for the third quarter of 2024 were $189 million and $1.81, respectively, compared to $156 million and $1.54 in the third quarter of 2023[5].

Key Financial Highlights

Several factors contribute to the financial health of Neurocrine Biosciences and the success of INGREZZA:

Operating Margin and Expenses

  • The company has seen an improvement in operating margin, driven by higher INGREZZA net sales. This has contributed to increased Non-GAAP net income and earnings per share[5].
  • Research and Development (R&D) expenses have increased to support an expanded and advancing clinical portfolio, including investments in muscarinic compounds, gene therapy programs, and second-generation VMAT2 inhibitors[2].

Cash and Marketable Securities

  • As of September 30, 2024, Neurocrine Biosciences had cash, cash equivalents, and marketable securities totaling approximately $1.9 billion, providing a strong financial foundation for continued investment in research and development[5].

Clinical Success and Regulatory Developments

The clinical success of INGREZZA is a significant factor in its market dynamics.

Clinical Outcomes

  • Recent studies have shown that INGREZZA can achieve remission in patients with tardive dyskinesia, aligning well with the company's strong financial performance[3].

Regulatory Updates

  • The FDA has granted Priority Review for crinecerfont, another Neurocrine Biosciences drug, for the treatment of congenital adrenal hyperplasia in adults and pediatrics. This indicates a deep and focused neuroscience pipeline that supports the company's growth[5].

Expansion and Strategic Initiatives

Neurocrine Biosciences is taking several strategic steps to further enhance the market presence of INGREZZA:

Sales Team Expansion

  • The company has announced plans to expand the INGREZZA psychiatry and long-term care sales teams to better serve patients and capitalize on the drug's growing demand[1].

New Formulations

  • A new sprinkle formulation of INGREZZA capsules has been launched, making the drug more accessible and convenient for patients with tardive dyskinesia[1].

Share Repurchase Plan

  • The board has authorized a $300 million share repurchase plan, reflecting the company's confidence in its financial health and future growth prospects[5].

Industry Impact and Analyst Projections

The success of INGREZZA has significant implications for the broader pharmaceutical industry.

Market Influence

  • The robust growth of INGREZZA is influencing analyst projections, with revised earnings upwards for the upcoming period. This is partly due to the positive clinical outcomes and the potential for increased adoption of the drug[3].

Financial Health

  • Neurocrine Biosciences' financial health, with a gross profit margin of 68.07% and an operating income margin of 26.85% over the last twelve months, positions the company well for continued investment in research and development[3].

Key Takeaways

  • Strong Sales Growth: INGREZZA has shown significant year-over-year growth, driven by strong patient demand and improvements in gross-to-net dynamics.
  • Financial Performance: The drug's success has translated into robust financial gains for Neurocrine Biosciences, with increased revenue, net income, and earnings per share.
  • Clinical Success: Positive clinical outcomes, including remission in tardive dyskinesia patients, support the drug's market success.
  • Strategic Initiatives: Expansion of sales teams, new formulations, and a share repurchase plan indicate the company's confidence in INGREZZA's future growth.

FAQs

What is INGREZZA used for?

INGREZZA (valbenazine) is used to treat tardive dyskinesia and chorea associated with Huntington's disease.

How has INGREZZA performed financially in 2024?

INGREZZA has shown strong financial performance in 2024, with second-quarter net product sales of $580 million and third-quarter sales of $613 million, representing year-over-year growth of 32% and 26%, respectively.

What are the key factors driving INGREZZA's growth?

The growth of INGREZZA is driven by strong underlying patient demand, improvements in gross-to-net dynamics, and the drug's clinical success in treating tardive dyskinesia and Huntington's disease chorea.

What are Neurocrine Biosciences' plans for expanding INGREZZA's market presence?

Neurocrine Biosciences plans to expand the INGREZZA psychiatry and long-term care sales teams and has launched a new sprinkle formulation of INGREZZA capsules.

How does INGREZZA's success impact Neurocrine Biosciences' financial health?

INGREZZA's success has contributed to Neurocrine Biosciences' strong financial health, with a gross profit margin of 68.07% and an operating income margin of 26.85% over the last twelve months, enabling the company to continue investing in research and development.

Sources

  1. Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance. PR Newswire.
  2. Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results. Neurocrine Biosciences.
  3. INGREZZA shows tardive dyskinesia remission in study. Investing.com.
  4. Neurocrine Biosciences Reports Third Quarter 2024 Financial Results. Neurocrine Biosciences.
  5. Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance. PR Newswire.
Last updated: 2024-12-16

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.